There was also a reduction in tumor regrowth after drug withdrawal in the EGFR-mutant PDX model TH021, LU-01-1291, and LU1868 (Fig. 4h–j), with no indication of substantial overall toxicity in preliminary studies (Supplementary Fig. 8h, i). This evidence concerns the gene EGFR and neoplasm.